Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8981070rdf:typepubmed:Citationlld:pubmed
pubmed-article:8981070lifeskim:mentionsumls-concept:C0006644lld:lifeskim
pubmed-article:8981070lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:8981070lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:8981070lifeskim:mentionsumls-concept:C0010583lld:lifeskim
pubmed-article:8981070lifeskim:mentionsumls-concept:C0971858lld:lifeskim
pubmed-article:8981070lifeskim:mentionsumls-concept:C0003865lld:lifeskim
pubmed-article:8981070lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:8981070lifeskim:mentionsumls-concept:C1527144lld:lifeskim
pubmed-article:8981070lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:8981070lifeskim:mentionsumls-concept:C1527240lld:lifeskim
pubmed-article:8981070lifeskim:mentionsumls-concept:C0536760lld:lifeskim
pubmed-article:8981070pubmed:issue7lld:pubmed
pubmed-article:8981070pubmed:dateCreated1997-4-1lld:pubmed
pubmed-article:8981070pubmed:abstractText1. Cofpropamine (Cofa), a caffeine derivative that inhibits polyadenoribosylation, enhances the therapeutic effect of cyclophosphamide (CPA) in two animal models of arthritis. 2. The development of adjuvant arthritis of rats is reduced by treatment with 2 x 50 mg/kg IP CPA and 2 x 50 mg/kg IP Cofa. 3. The development of collagen arthritis in mice is prevented by treatment with 12.5 mg/kg IP CPA and 150 mg/kg IP Cofa three times per week.lld:pubmed
pubmed-article:8981070pubmed:languageenglld:pubmed
pubmed-article:8981070pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8981070pubmed:citationSubsetIMlld:pubmed
pubmed-article:8981070pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8981070pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8981070pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8981070pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8981070pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8981070pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8981070pubmed:statusMEDLINElld:pubmed
pubmed-article:8981070pubmed:monthOctlld:pubmed
pubmed-article:8981070pubmed:issn0306-3623lld:pubmed
pubmed-article:8981070pubmed:authorpubmed-author:KrögerHHlld:pubmed
pubmed-article:8981070pubmed:authorpubmed-author:WildAAlld:pubmed
pubmed-article:8981070pubmed:authorpubmed-author:GrätzRRlld:pubmed
pubmed-article:8981070pubmed:authorpubmed-author:DietrichAAlld:pubmed
pubmed-article:8981070pubmed:authorpubmed-author:KlosaJJlld:pubmed
pubmed-article:8981070pubmed:authorpubmed-author:EhrlichWWlld:pubmed
pubmed-article:8981070pubmed:issnTypePrintlld:pubmed
pubmed-article:8981070pubmed:volume27lld:pubmed
pubmed-article:8981070pubmed:ownerNLMlld:pubmed
pubmed-article:8981070pubmed:authorsCompleteYlld:pubmed
pubmed-article:8981070pubmed:pagination1215-8lld:pubmed
pubmed-article:8981070pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:8981070pubmed:meshHeadingpubmed-meshheading:8981070-...lld:pubmed
pubmed-article:8981070pubmed:meshHeadingpubmed-meshheading:8981070-...lld:pubmed
pubmed-article:8981070pubmed:meshHeadingpubmed-meshheading:8981070-...lld:pubmed
pubmed-article:8981070pubmed:meshHeadingpubmed-meshheading:8981070-...lld:pubmed
pubmed-article:8981070pubmed:meshHeadingpubmed-meshheading:8981070-...lld:pubmed
pubmed-article:8981070pubmed:meshHeadingpubmed-meshheading:8981070-...lld:pubmed
pubmed-article:8981070pubmed:meshHeadingpubmed-meshheading:8981070-...lld:pubmed
pubmed-article:8981070pubmed:meshHeadingpubmed-meshheading:8981070-...lld:pubmed
pubmed-article:8981070pubmed:meshHeadingpubmed-meshheading:8981070-...lld:pubmed
pubmed-article:8981070pubmed:meshHeadingpubmed-meshheading:8981070-...lld:pubmed
pubmed-article:8981070pubmed:meshHeadingpubmed-meshheading:8981070-...lld:pubmed
pubmed-article:8981070pubmed:meshHeadingpubmed-meshheading:8981070-...lld:pubmed
pubmed-article:8981070pubmed:meshHeadingpubmed-meshheading:8981070-...lld:pubmed
pubmed-article:8981070pubmed:meshHeadingpubmed-meshheading:8981070-...lld:pubmed
pubmed-article:8981070pubmed:meshHeadingpubmed-meshheading:8981070-...lld:pubmed
pubmed-article:8981070pubmed:meshHeadingpubmed-meshheading:8981070-...lld:pubmed
pubmed-article:8981070pubmed:meshHeadingpubmed-meshheading:8981070-...lld:pubmed
pubmed-article:8981070pubmed:year1996lld:pubmed
pubmed-article:8981070pubmed:articleTitleThe therapeutic effect of a combination of cofpropamine, a caffeine derivative, and cyclophosphamide on the development of adjuvant arthritis of rats and collagen arthritis of mice.lld:pubmed
pubmed-article:8981070pubmed:affiliationDeutsches Rheumaforschungszentrum Berlin, Germany.lld:pubmed
pubmed-article:8981070pubmed:publicationTypeJournal Articlelld:pubmed